Company profile
Noveris Health Sciences Inc.
OTC: MYCOF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Vancouver, BCReports USD
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH 45DQ —GM —SS 30
v0.1 · 35/100 weight · pillars only
↑ return on assets, Piotroski F · ↓ balance-sheet leverage, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$2.1M
Employees
3
as of 2026-08-18
Market cap
$42.7M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income$2.1M2.9M CAD2025
Operating income-$393.4k-549.9k CAD2025
Total assets$7.1k9.7k CAD2025
Liabilities$9.1M12.5M CAD2025
Equity-$9.1M-12.5M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Noveris Health Sciences Inc.’s revenue?
Noveris Health Sciences Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a Infinity% net margin.
Peers · Healthcare
Arch Biopartners Inc.13DInstil Bio, Inc.36DTenax Therapeutics, Inc.49DGrace Therapeutics, Inc.48DNanoViricides, Inc.35DLite Strategy, Inc.49DKey facts
CEOJason Birmingham
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersVancouver, BC
ExchangeOTC: MYCOF
Employees3
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.